Farallon Capital Management LLC Boosts Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Farallon Capital Management LLC boosted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 11.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,865,100 shares of the biotechnology company's stock after purchasing an additional 285,100 shares during the period. Sarepta Therapeutics makes up 1.8% of Farallon Capital Management LLC's holdings, making the stock its 20th biggest holding. Farallon Capital Management LLC owned 3.00% of Sarepta Therapeutics worth $348,368,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Sarepta Therapeutics by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company's stock valued at $1,104,701,000 after purchasing an additional 117,904 shares in the last quarter. Capital International Investors lifted its position in shares of Sarepta Therapeutics by 38.9% during the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock worth $1,057,482,000 after buying an additional 2,437,855 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its position in shares of Sarepta Therapeutics by 0.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,956,583 shares of the biotechnology company's stock worth $237,901,000 after buying an additional 10,343 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Sarepta Therapeutics by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 1,706,353 shares of the biotechnology company's stock worth $207,538,000 after buying an additional 9,999 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Sarepta Therapeutics during the 4th quarter worth approximately $126,315,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now owns 27,812 shares in the company, valued at $2,771,187.68. The trade was a 8.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 7.70% of the stock is owned by corporate insiders.

Sarepta Therapeutics Trading Down 1.0%

Shares of NASDAQ SRPT traded down $0.36 during trading on Wednesday, hitting $35.84. 3,335,792 shares of the company traded hands, compared to its average volume of 1,675,271. The company has a 50-day moving average price of $64.03 and a 200-day moving average price of $99.33. The firm has a market capitalization of $3.52 billion, a P/E ratio of 28.67 and a beta of 0.85. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 1 year low of $34.90 and a 1 year high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The firm had revenue of $744.86 million during the quarter, compared to analysts' expectations of $685.75 million. During the same quarter last year, the business earned $0.73 earnings per share. The business's revenue for the quarter was up 80.2% compared to the same quarter last year. On average, equities analysts predict that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently commented on SRPT shares. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research report on Wednesday, March 19th. Wells Fargo & Company reduced their price target on shares of Sarepta Therapeutics from $115.00 to $100.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. HC Wainwright cut their price objective on shares of Sarepta Therapeutics from $75.00 to $40.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. The Goldman Sachs Group cut their price objective on shares of Sarepta Therapeutics from $178.00 to $100.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, Cantor Fitzgerald cut their price objective on Sarepta Therapeutics from $163.00 to $81.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Six equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $131.22.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.